ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Global research hotspots and evolving themes in chemoresistance of hepatocellular carcinoma: a bibliometric analysis from a pharmacological perspective.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Chemoresistance in hepatocellular carcinoma (HCC) complicates treatment and poses a substantial and growing burden to healthcare systems worldwide. Despite remarkable advances in recent years, the massive volume of publications has made it hard to identify overarching trends, critical turning points, and emerging frontiers. The present study aimed to conduct a comprehensive analysis of the global research landscape and summarize future hotspots. Articles on chemoresistance in HCC published in the Science Citation Index Expanded, Web of Science Core Collection, from 1991 to 2025 were searched. Bibliometrix (R package) was used for data analysis and visualization. CiteSpace was employed for keywords bursts detection. A total of 2571 publications by 12243 authors from 643 sources were included. An increase in the annual growth in the number of publications and citations was observed. Cancers had the most publications, and Cancer Research was the most cited. China and the USA are the dominant countries in this field. Sun Yat Sen University is the most productive affiliation. Wang Y is the most productive author. Besides topic-relevant keywords, terms like "expression," "apoptosis, " and "metastasis," etc. had high occurrence. Thematic shifts were also identified, transitioning from single-agent and single-target approaches to complex combination therapies and novel technological interventions. Conclusively, through a bibliometric analysis of publications, the present work shows key developments in the field of chemoresistance in HCC. Potential research hotspots include advanced combinatorial nano-immunotherapy, ferroptosis inducers, combined immunotherapy, and metabolic plasticity and stemness pathway regulators of cancer stem cells.
Indexed as
Identifiers
42307640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.